ZA200701427B - 4-(phenylmethyl and substituted phenylmethyl)-imizadole-2-thiones acting as specific alpha2 adrenergic agonists - Google Patents

4-(phenylmethyl and substituted phenylmethyl)-imizadole-2-thiones acting as specific alpha2 adrenergic agonists

Info

Publication number
ZA200701427B
ZA200701427B ZA200701427A ZA200701427A ZA200701427B ZA 200701427 B ZA200701427 B ZA 200701427B ZA 200701427 A ZA200701427 A ZA 200701427A ZA 200701427 A ZA200701427 A ZA 200701427A ZA 200701427 B ZA200701427 B ZA 200701427B
Authority
ZA
South Africa
Prior art keywords
phenylmethyl
imizadole
adrenergic agonists
substituted
alpha2 adrenergic
Prior art date
Application number
ZA200701427A
Other languages
English (en)
Inventor
Todd M Heidelbaugh
Phong X Nguyen
John E Donello
Larry A Wheeler
Chow Ken
Daniel W Gil
Michael E Garst
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of ZA200701427B publication Critical patent/ZA200701427B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA200701427A 2004-09-24 2007-02-19 4-(phenylmethyl and substituted phenylmethyl)-imizadole-2-thiones acting as specific alpha2 adrenergic agonists ZA200701427B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US61292304P 2004-09-24 2004-09-24

Publications (1)

Publication Number Publication Date
ZA200701427B true ZA200701427B (en) 2008-08-27

Family

ID=35559467

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200701427A ZA200701427B (en) 2004-09-24 2007-02-19 4-(phenylmethyl and substituted phenylmethyl)-imizadole-2-thiones acting as specific alpha2 adrenergic agonists

Country Status (17)

Country Link
US (1) US7683089B1 (ja)
EP (1) EP1797043A1 (ja)
JP (1) JP2008514601A (ja)
KR (1) KR20070054213A (ja)
CN (1) CN101031549A (ja)
AR (1) AR051107A1 (ja)
AU (1) AU2005290075A1 (ja)
BR (1) BRPI0516083A (ja)
CA (1) CA2581579A1 (ja)
IL (1) IL181749A0 (ja)
MX (1) MX2007003068A (ja)
NO (1) NO20071403L (ja)
NZ (1) NZ553341A (ja)
RU (2) RU2383535C2 (ja)
TW (1) TW200626147A (ja)
WO (1) WO2006036480A1 (ja)
ZA (1) ZA200701427B (ja)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1981880B1 (en) * 2006-01-27 2010-02-24 F.Hoffmann-La Roche Ag Use of 4-imidazole derivatives for cns disorders
EP1918282A1 (en) * 2006-11-06 2008-05-07 "Joint Stock Company Grindeks" Method for preparing medetomidine and its salts
WO2009052072A1 (en) * 2007-10-18 2009-04-23 Allergan, Inc. Treating motor disorders with 4-(1-(2,3-dimethylphenyl)ethyl)-1h-imidazole-2(3h)-thione
WO2009052073A2 (en) * 2007-10-18 2009-04-23 Allergan, Inc. Method of treating sensorimotor disorders with alpha-2 adrenergic receptor agonists
JP2012518005A (ja) * 2009-02-13 2012-08-09 アラーガン インコーポレイテッド ４‐（１‐（３‐（ヒドロキシメチル）‐２‐メチルフェニル）エチル）‐１ｈ‐イミダゾール‐２（３ｈ）‐チオン
EP2605771B1 (en) * 2010-08-16 2018-04-04 Allergan, Inc. Method of activating regulatory t cells with alpha-2b adrenergic receptor agonists
US8492557B2 (en) * 2010-09-16 2013-07-23 Allergan, Inc. Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol
CA2856507C (en) 2011-11-21 2017-03-21 Allergan, Inc. Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3h-imidazole derivatives for treating retinal diseases
CN105884691B (zh) * 2016-06-02 2017-08-25 江苏恒瑞医药股份有限公司 一种制备右美托咪定及其中间体的方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU795462A3 (ru) 1975-03-14 1981-01-07 Эдьт Дьедьесерведьесети Дьяр (Фирма) Способ получени тиокарбамидныхпРОизВОдНыХ
US4798843A (en) * 1987-07-09 1989-01-17 Smithkline Beckman Corporation 2-mercaproimidazole dopamine-β-hydroxylase inhibitors
JPH0667368A (ja) 1992-08-13 1994-03-11 Fuji Photo Film Co Ltd 黒白ハロゲン化銀写真感光材料の現像方法
ZA971896B (en) 1996-03-26 1998-09-07 Du Pont Merck Pharma Aryloxy-and arythio-fused pyridines and pyrimidines and derivatives
KR100365312B1 (ko) 1996-06-27 2003-03-06 얀센 파마슈티카 엔.브이. N-[4-(헤테로아릴메틸)페닐]헤테로아릴아민
AU727520B2 (en) 1997-11-28 2000-12-14 Mitsubishi Chemical Corporation A handle for a plastic bottle and a plastic bottle with a handle
US6841684B2 (en) * 1997-12-04 2005-01-11 Allergan, Inc. Imidiazoles having reduced side effects
TWI283669B (en) * 1999-06-10 2007-07-11 Allergan Inc Compounds and method of treatment having agonist-like activity selective at alpha 2B or 2B/2C adrenergic receptors
WO2001000568A1 (fr) * 1999-06-28 2001-01-04 Meiji Seika Kaisha, Ltd. Derives hydrazones et pesticides
JP2002097310A (ja) 2000-09-25 2002-04-02 Bridgestone Corp タイヤ
JP2002097312A (ja) 2000-09-26 2002-04-02 Bridgestone Corp タイヤ
AU2002248284A1 (en) 2000-11-01 2002-08-06 Allergan, Inc. Compositions for treatment of ocular neovascularization
ATE301125T1 (de) * 2001-01-30 2005-08-15 Zenyaku Kogyo Kk Heterocyclische verbindungen und mittel, die die hirnfunktion verbessern und als wirkstoff diese verbindungen enthalten
JP2004525942A (ja) * 2001-03-29 2004-08-26 スミスクライン・ビーチャム・コーポレイション 化合物および方法
US7345065B2 (en) * 2002-05-21 2008-03-18 Allergan, Inc. Methods and compositions for alleviating pain
US7323485B2 (en) * 2002-05-21 2008-01-29 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
US7091232B2 (en) * 2002-05-21 2006-08-15 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
US7141597B2 (en) * 2003-09-12 2006-11-28 Allergan, Inc. Nonsedating α-2 agonists
US20050059664A1 (en) * 2003-09-12 2005-03-17 Allergan, Inc. Novel methods for identifying improved, non-sedating alpha-2 agonists

Also Published As

Publication number Publication date
TW200626147A (en) 2006-08-01
WO2006036480A1 (en) 2006-04-06
MX2007003068A (es) 2007-05-21
RU2009141800A (ru) 2011-05-20
RU2007110711A (ru) 2008-10-27
IL181749A0 (en) 2007-07-04
NO20071403L (no) 2007-05-22
CN101031549A (zh) 2007-09-05
RU2383535C2 (ru) 2010-03-10
BRPI0516083A (pt) 2008-08-19
AR051107A1 (es) 2006-12-20
JP2008514601A (ja) 2008-05-08
EP1797043A1 (en) 2007-06-20
KR20070054213A (ko) 2007-05-28
CA2581579A1 (en) 2006-04-06
US7683089B1 (en) 2010-03-23
NZ553341A (en) 2010-11-26
AU2005290075A1 (en) 2006-04-06

Similar Documents

Publication Publication Date Title
IL181749A0 (en) 4-(phenylmethyl and substituted phenylmethyl)-imidazole-2-thiones acting as specific alpha2 adrenergic agonists
HUS1800010I1 (hu) 4-Fenil-6-(2,2,2-trifluor-1-feniletoxi)pirimidin-alapú vegyületek és alkalmazási eljárásaik
IL177007A0 (en) 2-(3-substituted-aryl) amino-4-thiazoles as tyrosine kinase inhibitors
IL211491A0 (en) 4-(benzimidazolylmethylamino)-benzamidines
ZA200700084B (en) 2,4-DI(aminopheyl) pyrimidines AS PKL inhibitors
PL2200985T3 (pl) 1,3-Dipodstawione-4-(arylo-X-fenylo)-1H-pirydyn-2-ony
ZA200803926B (en) 2-(Phenyl or heterocyclic)-1H-phenantrho[9,10-D]imidazoles as MPGES-1 inhibitors
HK1163019A1 (en) Chip holder
AP2007003924A0 (en) Imidazopyrazine as tyrosine kinase inhibitors
EP1836815A4 (en) DYNAMIC AND INTELLIGENT BUFFER MANAGEMENT FOR SAN NETWORK EXTENSION
ATE508119T1 (de) Ä4,5'ü-bipyrimidinyl-6,4'-diaminderivate als proteinkinase-hemmer
HK1090926A1 (en) Pyrazolopyrimidine-derivatives as cyclin dependent kinase inhibitors
EP1828143A4 (en) 1H-PHENANTHRO [9,10-D] IMIDAZOLES SUBSTITUTED INTO 2 BY PHENYL OR HETEROCYCLE AS INHIBITORS OF MPGES-1
HK1105415A1 (en) Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
DE602006016303D1 (de) 3,4-dihydro-2H-benzoÄ1,4Üoxazin- und 3,4-dihydro-2H-benzoÄ1,4Üthiazin-VERBINDUNGEN ALS ALPHA2C-ADRENOREZEPTOR-ANTAGONISTEN
EP1948193A4 (en) AMINOPYRIMIDINES SUITABLE AS KINASEINHIBITORS
DE602006015418D1 (de) Merkmalsextraktion unter Verwendung von Pixel- und Objekteigenschaften
PT1928840E (pt) 1h-pirazole-4-carboxamidas, a sua preparação e a sua utilização a título de inibidores de 11-betahidroxiesteróide desidrogenase
ZA200804241B (en) [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2H-quina-zolin-3-yl)-phenyl]-5-chlorothiophen-2-yl-sulfonylureas and forms and methods related thereto
ZA200707139B (en) Pyrazine -2-carboxamide derivatives as mGluR5 antagonists
IL178031A0 (en) [4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(4-bromo-3-methyl-5-propoxy-thiophen-2-yl)-methanone hydrochloride as an inhibitor of mast cell tryptase
IL181677A0 (en) Substituted heterocyclic compounds and uses thereof
EP1922544A4 (en) METHOD FOR DETERMINING TENSIONS APPEARING IN WOOD DURING DRYING
EP1945624A4 (en) CHROMIN COMPOUNDS AS 5-HT1B ANTAGONISTS
ZA200700162B (en) Novel heterocyclic compounds